Hamlet BioPharma AB (publ): Briefglance Highlights Hamlet BioPharma's Collaboration with the University of Iowa and the Potential for Advanced Bladder Cancer Therapy
The digital analytics platform Briefglance has highlighted Hamlet BioPharma's collaboration with the University of Iowa regarding the development of Alpha1H treatment for patients with severe bladder cancer. The article outlines the advanced scientific and clinical background, the importance of the collaboration and its significance for Hamlet BioPharma.
Among other observations, Briefglance describes Alpha1H as a promising treatment candidate for patients who do not respond to BCG therapy; a patient population for whom treatment options remain limited.
Briefglance is a U.S.-focused digital platform providing in-depth business analysis and market intelligence for investors, analysts, and decision-makers, with the aim of helping readers better understand the factors shaping industries and financial markets.
Link to the article: https://briefglance.com/articles/beyond-bcg-breast-milk-derived-drug-enters-us-trials-for-resistant-cancer
For further information, please contact
Catharina Svanborg, Chairman of the Board, Hamlet BioPharma AB, +46 709 42 65 49
catharina.svanborg@hamletpharma.com
Jakob Testad, CEO, Hamlet BioPharma AB, +46 708 48 42 10
jakob.testad@hamletbiopharma.com